BiondVax Pharmaceuticals Ltd. announced that its patent application in the United States titled "Multimeric Multi-Epitope Polypeptides in Improved Seasonal and Pandemic Influenza Vaccines" has completed examination and is allowed for issuance as a patent. The invention covers the use of BiondVax's universal flu vaccine as a prime-boost to the current commercially available flu vaccine. Results from BiondVax's completed clinical trials have shown significantly increased effectiveness against multiple flu strains.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.125 USD | +4.87% |
|
-2.34% | -47.51% |
02/07 | Scinai Immunotherapeutics Ltd. Provides Earnings Guidance for 2024 | CI |
02/07 | Scinai Immunotherapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-47.51% | 1.38M | |
+16.59% | 44.87B | |
-10.62% | 37.8B | |
+40.49% | 37.61B | |
+29.92% | 31.32B | |
-9.78% | 27.4B | |
+12.34% | 26.32B | |
+41.53% | 14.07B | |
+31.49% | 12.5B | |
-7.40% | 11.23B |
- Stock Market
- Equities
- BVXV Stock
- News Scinai Immunotherapeutics Ltd.
- BiondVax's Universal Flu Vaccine Receives Additional US Patent